Clinical Guides
Polycythaemia and Erythrocytosis
A clinically focused, India-adapted guide to confirming erythrocytosis, separating relative and secondary causes from polycythaemia vera, preventing thrombosis, and recognising urgent complications.
MedNext Academy | 14 min read
Polycythaemia and Erythrocytosis
A clinically focused, India-adapted guide to confirming erythrocytosis, separating relative and secondary causes from polycythaemia vera, preventing thrombosis, and recognising urgent complications.
Summary
Polycythaemia is a familiar clinical label, but erythrocytosis is the more precise description of an increased circulating red-cell concentration or mass. A raised haemoglobin or haematocrit may reflect true expansion of red-cell mass, reduced plasma volume, or both. Absolute erythrocytosis is then divided into primary disease, where the marrow produces red cells autonomously, and secondary disease driven by erythropoietin or tissue hypoxia. Polycythaemia vera is an acquired clonal myeloproliferative neoplasm, usually associated with a JAK2 mutation; it is not synonymous with every high haematocrit.
The diagnostic task is therefore sequential. Confirm persistence and exclude sampling or volume effects, look for hypoxia, smoking or carbon-monoxide exposure, obstructive sleep apnoea, cardiopulmonary disease, renal pathology and medicines such as testosterone or exogenous erythropoietin, then use serum erythropoietin, JAK2 testing and specialist marrow assessment when appropriate. A normal pulse-oximetry reading does not exclude sleep-related hypoxia, carbon monoxide exposure or a high-affinity haemoglobin. Dual pathology is possible.
The principal preventable harm in polycythaemia vera is arterial or venous thrombosis; haemorrhage, troublesome microvascular symptoms, pruritus, splenic symptoms and transformation to myelofibrosis or acute leukaemia also matter. Treatment commonly combines control of cardiovascular risk, venesection to a protocolled haematocrit target, antiplatelet therapy when safe, and cytoreduction for defined risk or symptom indications. Secondary erythrocytosis is treated by addressing its cause, and routine venesection is not automatically beneficial. This educational draft does not replace a haematology plan and has been reviewed by the MedNext Clinical Team.
How Common Is It?
An isolated high haemoglobin is encountered far more often than confirmed polycythaemia vera. Dehydration, diuretics, smoking, altitude exposure, chronic hypoxaemia, sleep-disordered breathing, testosterone and laboratory variation all influence the measured concentration. The proportion attributable to each cause depends on the population and referral threshold. A tertiary myeloproliferative-neoplasm clinic therefore cannot supply prevalence for a primary-care district, and a single blood count cannot define a chronic disorder.
Polycythaemia vera is uncommon. The British Society for Haematology guideline reports a median presentation age around 60 years, while recognising incidental diagnosis and presentation with thrombosis. Age distribution does not exclude younger adults, and rare congenital erythrocytoses may present in childhood or cluster in families. International incidence estimates vary with diagnostic criteria, registry completeness, access to JAK2 testing and whether masked disease is recognised. They should not be copied as an Indian national rate.
India does not have one complete, contemporaneous population registry for every erythrocytosis aetiology. Apparent burden varies between high-altitude communities, urban populations with sleep apnoea and metabolic disease, tobacco-exposed groups, regions with chronic cardiopulmonary illness, and referral centres offering molecular diagnostics. Private laboratory screening may increase incidental detection, whereas limited access may delay it until thrombosis or marked symptoms occur. The practical epidemiological message is not that every borderline result represents PV. It is that a persistent elevation deserves a structured cause-based assessment, particularly when accompanied by thrombosis, splenomegaly, leucocytosis, thrombocytosis or vasomotor symptoms. Local laboratory reference intervals, sex, pregnancy status, altitude and hydration must be considered before interpreting the number.
Risk Factors
Risk factors for an increased red-cell concentration depend on mechanism. Relative erythrocytosis accompanies reduced plasma volume from dehydration, vomiting, diarrhoea, diuretic exposure or other volume loss. Hypoxia-driven secondary erythrocytosis can occur with chronic lung disease, cyanotic congenital heart disease, right-to-left shunts, obstructive sleep apnoea, prolonged residence at altitude or carbon-monoxide exposure. Cigarettes, bidis, hookah and indoor combustion may contribute through carbon monoxide or respiratory disease; a normal clinic oxygen saturation does not reliably exclude these pathways.
Non-hypoxic secondary causes include exogenous erythropoietin, testosterone or anabolic-androgenic steroids, some renal disorders and erythropoietin-producing tumours. Renal artery stenosis, cystic or obstructive kidney disease, renal-cell carcinoma and selected hepatic or other tumours belong in a targeted differential, not an indiscriminate whole-body scan. Young age, lifelong elevation and affected relatives raise the possibility of an erythropoietin-receptor variant, altered oxygen sensing, high-affinity haemoglobin or 2,3-bisphosphoglycerate deficiency.
Polycythaemia vera results from an acquired haematopoietic clone, most often JAK2 V617F and less often a JAK2 exon 12 variant. It is not caused by dehydration, diet or stress, though those factors can alter its measured expression. Once PV is present, previous thrombosis and increasing age strongly influence vascular risk; hypertension, diabetes, dyslipidaemia, smoking and obesity add modifiable risk. Leucocytosis, high symptom burden, frequent venesection requirement and splenomegaly may influence specialist decisions without replacing validated risk assessment. Iron deficiency can mask the erythrocytosis, particularly when microcytosis is present. Pregnancy, surgery and splanchnic or cerebral venous thrombosis are special contexts requiring early specialist planning.
Diagnosis
History
Establish whether the abnormality is persistent, its trajectory and the laboratory context. Ask about headache, dizziness, visual disturbance, erythromelalgia, aquagenic pruritus, fatigue, night sweats, weight loss, early satiety, gout, bleeding and prior arterial, venous or unusual-site thrombosis. Record vomiting, diarrhoea, reduced intake, altitude, snoring, witnessed apnoea, daytime somnolence, chronic cough, dyspnoea, cyanosis, tobacco and combustion exposure. Review testosterone, anabolic steroids, erythropoietin, diuretics and supplements. Ask about renal disease, transplantation, cardiac disease and relatives with lifelong high counts or early thrombosis.
Examination
Repeat vital signs after rest and assess hydration. Look for plethoric appearance without treating it as diagnostic, cyanosis, clubbing, cardiopulmonary disease, obesity and signs of sleep-disordered breathing. Measure blood pressure and examine pulses, heart, lungs, abdomen and spleen. Seek hepatomegaly, renal or abdominal masses only through appropriate examination, and assess neurological, retinal or limb findings when thrombosis is suspected. Bruising or mucosal bleeding may coexist with a high platelet count or acquired von Willebrand disease.
Investigations
Confirm the full blood count on a properly collected venous sample and review prior results, indices, white cells, platelets and blood film. Check ferritin, renal and liver profiles; select urate and lactate dehydrogenase by context. Pulse oximetry is a screening tool, not a complete exclusion test. Carboxyhaemoglobin, sleep assessment, arterial blood gas, echocardiography, pulmonary testing or abdominal imaging should answer a clinical question. Serum erythropoietin and peripheral-blood JAK2 V617F are central first-line discriminators in persistent absolute erythrocytosis; JAK2 exon 12 testing, marrow biopsy, red-cell-mass measurement or germline studies are specialist-directed. Apply one current diagnostic classification consistently rather than mixing thresholds from different systems.
Differential Diagnosis
The first distinction is relative versus absolute erythrocytosis. Haemoconcentration from fluid loss or diuresis raises haemoglobin and haematocrit without expanding red-cell mass. Apparent erythrocytosis may persist despite a normal measured red-cell mass. Repeating the count after clinical correction of volume status can prevent an unnecessary neoplasm work-up, but a striking or symptomatic elevation should not be dismissed as dehydration without evidence. Laboratory misidentification, venous stasis and method variation also deserve exclusion.
Secondary absolute erythrocytosis is much more heterogeneous. Central hypoxia from chronic lung disease, sleep apnoea or altitude; circulatory hypoxia from shunts; local renal hypoxia; smoking or carbon monoxide; exogenous erythropoietin; androgen exposure; renal and selected other tumours; and post-transplant erythrocytosis require different investigations. Normal resting saturation can coexist with nocturnal desaturation, carbon monoxide exposure or high-affinity haemoglobin. Serum erythropoietin may guide the pathway but is not a stand-alone verdict.
Primary alternatives include congenital erythropoietin-receptor signalling abnormalities and polycythaemia vera. PV may show leucocytosis, thrombocytosis, splenomegaly, low erythropoietin, marrow panmyelosis and a JAK2 mutation, but no single peripheral count distinguishes it in every patient. Iron deficiency may produce microcytosis and obscure the expected haemoglobin. Essential thrombocythaemia or prefibrotic myelofibrosis can share JAK2 and overlapping marrow features.
Other explanations for symptoms must remain open: migraine can mimic microvascular headache; liver or dermatological disease can cause itching; and an incidental high count does not prove the cause of a stroke or venous thrombosis. Idiopathic erythrocytosis is a diagnosis reached after a proportionate assessment, not a convenient label before hypoxia, drug exposure and clonal disease have been considered.
Management
Treat physiological danger first. Suspected stroke, acute coronary syndrome, pulmonary embolism, splanchnic thrombosis, limb ischaemia, severe hyperviscosity symptoms or major bleeding requires emergency assessment and simultaneous haematology contact. Do not delay standard thrombosis care while debating whether an elevated count is primary or secondary. In confirmed PV, the long-term aim is to reduce vascular events, control symptoms and monitor evolution while minimising treatment toxicity.
A typical PV plan addresses smoking, blood pressure, diabetes, lipids, weight and mobility; uses protocolled venesection to maintain haematocrit below 0.45; and includes low-dose aspirin when there is no contraindication. The exact venesection interval follows counts, symptoms and tolerance. Cytoreduction is indicated for high thrombotic risk and may also be considered for difficult haematocrit control, progressive splenomegaly, persistent leucocytosis, extreme thrombocytosis, poor venesection tolerance or substantial symptom burden. Hydroxycarbamide and interferon-based treatment are established options; ruxolitinib is used in selected inadequate-response or intolerance pathways. Choice depends on age, pregnancy potential, prior therapy, comorbidity, access and current local authorization.
Secondary erythrocytosis management targets the driver: stop relevant exposure, optimise oxygenation or sleep apnoea care, manage cardiopulmonary or renal disease, and investigate an erythropoietin-producing lesion appropriately. Oxygen must be prescribed for a documented indication, and tobacco cessation support matters. Routine aspirin or venesection is not automatically justified in every secondary or idiopathic erythrocytosis; indiscriminate phlebotomy can worsen iron deficiency or oxygen delivery. Congenital disease needs specialist individualisation. Follow-up should document cause, target, thrombosis and bleeding history, symptoms, blood counts, treatment toxicity and the trigger for reassessment or marrow evaluation.
Prescribing Information
Medicines for polycythaemia vera require a verified diagnosis and a haematology-owned plan. Low-dose aspirin can reduce vascular risk in appropriate PV patients, but assess active bleeding, peptic ulceration, hypersensitivity, clinically important thrombocytopenia, interacting antithrombotics and acquired von Willebrand disease when platelets are extreme. Aspirin is not a reflex response to every raised haematocrit, and dual antiplatelet or anticoagulant combinations need a clear indication because bleeding risk rises. Gastric protection is selected by individual risk rather than added universally.
Hydroxycarbamide suppresses marrow production and requires baseline and serial blood counts, renal and hepatic assessment, counselling about cytopenias, mucocutaneous toxicity and infection, and review of reproductive considerations. Dose adjustment follows a specialist protocol and response; this guide deliberately supplies no regimen. Interferon formulations can be considered in younger people and selected pregnancy-related pathways, but flu-like symptoms, liver dysfunction, mood disturbance, autoimmune disease and formulation-specific monitoring must be discussed. Ruxolitinib can increase infection and herpes-zoster risk and may cause cytopenias, metabolic changes or rebound problems if stopped abruptly; tuberculosis, hepatitis and other infection assessment follows local policy.
Venesection is a procedure rather than a prescription shortcut. Confirm the target, volume, frequency, hydration plan and response, especially in older adults or people with cardiorespiratory disease. Do not replace iron routinely in PV simply because ferritin is low: iron may accelerate erythrocytosis, while symptomatic deficiency requires specialist balancing. In secondary hypoxic disease, unsupervised venesection can impair tissue oxygen delivery. Verify current CDSCO approval, Indian product information, pregnancy and lactation advice, drug interactions and institutional monitoring before prescribing. Provide written instructions for fever, bleeding, thrombosis symptoms, missed doses and planned surgery.
When to Refer
Refer persistent unexplained erythrocytosis to haematology when repeat testing confirms the abnormality and no correctable volume or obvious secondary cause explains it. Urgency increases with neurological or cardiopulmonary symptoms, prior thrombosis, splenomegaly, leucocytosis, thrombocytosis, low erythropoietin, a positive JAK2 result, rapidly rising counts or a very high haematocrit. A negative JAK2 V617F test does not end the pathway when suspicion remains; specialist testing may include JAK2 exon 12, marrow examination or congenital panels.
Refer to respiratory or sleep services for suspected hypoxic lung disease or obstructive sleep apnoea, and to cardiology or congenital-heart services for cyanosis or a shunt. Renal impairment, haematuria, renal imaging abnormalities or post-transplant erythrocytosis may need nephrology or urology. Suspected erythropoietin-producing tumour requires organ-specific assessment, not repeated empiric venesection. Young patients with lifelong elevation or a family cluster benefit from specialist genetics after acquired causes are addressed.
Every confirmed PV patient should have longitudinal haematology care. Arrange early multidisciplinary planning before pregnancy, surgery or invasive procedures and after splanchnic or cerebral venous thrombosis. Worsening splenomegaly, constitutional symptoms, new anaemia, leucoerythroblastosis, falling platelets, blasts or increasing transfusion need may indicate progression and deserves expedited marrow reassessment.
A useful Indian referral includes serial counts with reference intervals, altitude and hydration context, tobacco and medicine exposure, oxygen saturation, cardiopulmonary symptoms, renal and liver results, ferritin, erythropoietin and JAK2 results if already obtained, thrombosis and bleeding history, pregnancy status and current medicines. Do not delay transfer to obtain every test if the patient is unstable or has a suspected acute vascular event.
Red Flags
New unilateral weakness, speech disturbance, visual loss, confusion, severe focal headache, chest pain, acute dyspnoea, haemoptysis, a cold painful limb or unilateral swelling may represent arterial or venous thrombosis. Portal, hepatic, mesenteric or cerebral venous thrombosis can present with abdominal pain, ascites, gastrointestinal bleeding, headache or seizures and may reveal an occult myeloproliferative neoplasm even when the blood count is not dramatically high. Activate the relevant emergency pathway and contact haematology early.
Severe headache with visual change, altered consciousness, mucosal bleeding or marked hyperviscosity symptoms in a patient with a substantially elevated haematocrit needs urgent assessment. Do not arrange unsupervised blood donation as treatment. Major haemorrhage can coexist with PV, particularly with extreme thrombocytosis, acquired von Willebrand disease, portal hypertension or combined antithrombotic therapy. Stabilise bleeding, check the entire haemostatic picture and seek transfusion and haematology advice.
A high haematocrit plus hypoxaemia, cyanosis, respiratory distress or carbon-monoxide exposure is not automatically PV. Treat the oxygenation or toxic exposure emergency while clarifying the cause. In pregnant patients, severe headache, visual symptoms, chest pain, limb symptoms, abdominal pain, hypertension or bleeding requires urgent obstetric and haematology assessment.
During cytoreduction, fever, severe infection, mouth ulcers preventing intake, rapidly falling counts, jaundice, severe rash, mood crisis, unexpected bleeding or new thrombosis demands prompt review. New anaemia, blasts, progressive constitutional symptoms, increasing spleen size, bone pain or loss of count control may signal post-PV myelofibrosis, acute transformation, non-adherence or another illness. Red flags determine urgency; they do not establish the final aetiology.
Indian Clinical Context
Indian assessment must account for geographical, exposure and service variation. High-altitude residence or work can produce physiological adaptation, whereas travel from sea level gives a different history. Tobacco exposure may involve cigarettes, bidis or hookah, and household or occupational combustion can be relevant. Chronic obstructive lung disease, untreated sleep apnoea, cyanotic congenital heart disease, testosterone obtained outside supervised care and renal disease all require active enquiry. A label of 'secondary polycythaemia' without documenting the mechanism is not adequate.
Access to serum erythropoietin, JAK2 testing, calibrated molecular assays, marrow morphology, sleep studies and red-cell-mass measurement varies. A staged pathway is therefore important: confirm persistence, gather a high-yield history, examine, check oxygenation and routine organ function, and refer before ordering an uncoordinated panel. When a molecular sample is sent to a distant laboratory, record specimen type, assay, sensitivity and report wording. A JAK2 result must be interpreted with blood counts, marrow and clinical context, not as a generic cancer screen.
Treatment availability also varies. Venesection may be accessible but should not become the default for unclassified erythrocytosis. Cytoreductive agents, interferon formulations, ruxolitinib, molecular monitoring and specialist pregnancy support differ by centre and affordability. Verify CDSCO authorization, institutional formulary and monitoring rather than importing a UK or European pathway unchanged. Referral planning should consider travel, heat exposure, hydration, continuity of blood counts and the ability to attend repeated procedures.
The BSH and ELN sources offer strong diagnostic and management principles but were not written as Indian national guidelines. Their age cut-offs, drug availability and service assumptions must be reconciled locally. Patient education should explain the cause being investigated, symptoms requiring emergency care and why commercially marketed supplements, iron or repeated blood donation are not substitutes for diagnosis.
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 maps polycythaemia directly in Physiology competency PY2.5. It requires the learner to describe anaemias, polycythaemia and jaundice and discuss their physiological principles of management. The stated level is Know How, it is core, and suggested methods include large- and small-group teaching, a student seminar and early clinical exposure. This guide extends that physiological foundation without pretending that an undergraduate competency authorises independent specialist prescribing.
PY2.4 supplies the linked mechanism: describe erythropoiesis and its regulation in physiological and pathological situations. PY2.12 supports understanding and interpretation of haematocrit, while PY2.11 includes estimation of haemoglobin, red cells and indices. Learners should connect oxygen sensing, renal erythropoietin, marrow response and plasma volume to the observed count before memorising disease labels.
At the clinical-application level, a student should be able to recognise persistence, distinguish relative from absolute erythrocytosis, identify common hypoxic and drug-related causes, explain the role of erythropoietin and JAK2 testing, and recognise thrombosis or bleeding as urgent. They should understand that PV is a clonal myeloproliferative neoplasm and that secondary erythrocytosis is not treated automatically with the PV pathway.
Teaching can use paired cases: dehydration with transient haemoconcentration; sleep apnoea with secondary erythrocytosis; and JAK2-positive PV with vasomotor symptoms or thrombosis. Assessment should ask for a safe investigative sequence and jurisdiction-aware management principles. Direct mapping should preserve PY2.5 exactly, while integration can include pathology, pharmacology, respiratory medicine, cardiology, nephrology, oncology, genetics and communication.
Key Exam Pearls for NEET PG
Polycythaemia describes an increased red-cell concentration; erythrocytosis is the preferred precise term. Relative erythrocytosis reflects reduced plasma volume, whereas absolute erythrocytosis reflects increased red-cell mass. Primary erythrocytosis has autonomous marrow signalling; secondary erythrocytosis is driven by erythropoietin or hypoxia. Polycythaemia vera is a clonal myeloproliferative neoplasm, most often associated with JAK2 V617F and less often JAK2 exon 12.
A normal oxygen saturation does not exclude obstructive sleep apnoea, carbon-monoxide exposure or high-affinity haemoglobin. A high erythropoietin concentration supports a search for secondary drivers, whereas low erythropoietin increases suspicion for PV but is not independently diagnostic. PV often shows panmyelosis, so leucocytosis, thrombocytosis and splenomegaly can accompany erythrocytosis. Iron deficiency may mask PV by lowering cell size and limiting haemoglobin rise.
Major PV complications are arterial and venous thrombosis, microvascular symptoms, haemorrhage, pruritus, hyperuricaemia, post-PV myelofibrosis and acute leukaemic transformation. Standard prevention principles include haematocrit below 0.45, low-dose aspirin when safe, and control of cardiovascular risk. Cytoreduction is risk and indication based; hydroxycarbamide and interferon are major options, with ruxolitinib used in selected resistant or intolerant disease.
Do not extrapolate PV therapy to every secondary erythrocytosis. Treat hypoxia, sleep apnoea, tobacco or carbon-monoxide exposure, medicines, renal disease or tumour as appropriate. Venesection in secondary disease is selective because excessive reduction can impair oxygen delivery. For NMC, remember the direct PY2.5 mapping and link it to PY2.4 and PY2.12. In an answer, separate confirmation, cause, thrombotic risk and management rather than writing 'high Hb equals PV.'
Frequently Asked Questions
Does one high haemoglobin result mean that a patient has polycythaemia vera?
No. The result should be interpreted with haematocrit, indices, hydration, altitude, medicines, smoking and prior counts. Relative haemoconcentration and secondary erythrocytosis are common. Persistent unexplained elevation may require erythropoietin, JAK2 testing and haematology assessment; PV is an integrated diagnosis, not a conclusion from one number.
Can a normal pulse-oximetry reading rule out hypoxia-driven erythrocytosis?
No. Resting pulse oximetry can be normal in obstructive sleep apnoea, carbon-monoxide exposure and high-affinity haemoglobin disorders. History determines whether nocturnal assessment, carboxyhaemoglobin measurement or specialist testing is needed. Oxygen should not be prescribed solely because the haematocrit is high.
Should every patient with secondary erythrocytosis receive aspirin and regular venesection?
No. Evidence and thrombotic risk vary by cause. Management usually targets the underlying driver, while aspirin follows a separate cardiovascular or specialist indication. Venesection is selective because unnecessary removal can create iron deficiency or worsen oxygen delivery. A haematology plan should define any target and monitoring.
Why can iron deficiency make polycythaemia vera harder to recognise?
Iron restriction reduces haemoglobin synthesis and cell size, so an expanded clonal red-cell population may produce microcytosis without an obviously extreme haemoglobin. Ferritin and indices help interpretation. Iron should not be replaced automatically in confirmed PV because it can accelerate erythrocytosis; symptoms and treatment goals need specialist balancing.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic